Boston Partners Acquires 11,738 Shares of Haemonetics Corporation $HAE

Boston Partners raised its stake in shares of Haemonetics Corporation (NYSE:HAE) by 2.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 543,169 shares of the medical instruments supplier’s stock after acquiring an additional 11,738 shares during the period. Boston Partners owned approximately 1.13% of Haemonetics worth $40,660,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Zions Bancorporation National Association UT grew its stake in shares of Haemonetics by 8.0% during the 2nd quarter. Zions Bancorporation National Association UT now owns 46,621 shares of the medical instruments supplier’s stock valued at $3,478,000 after purchasing an additional 3,447 shares during the period. Parkside Financial Bank & Trust boosted its holdings in shares of Haemonetics by 11.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 152 shares during the last quarter. Bank of New York Mellon Corp grew its position in Haemonetics by 1.7% during the second quarter. Bank of New York Mellon Corp now owns 376,308 shares of the medical instruments supplier’s stock valued at $28,076,000 after buying an additional 6,256 shares during the period. Retirement Systems of Alabama increased its holdings in Haemonetics by 0.4% during the second quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock valued at $4,581,000 after buying an additional 256 shares during the last quarter. Finally, Keybank National Association OH bought a new position in Haemonetics in the second quarter worth approximately $303,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Citigroup cut their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Weiss Ratings lowered Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Raymond James Financial downgraded Haemonetics from a “strong-buy” rating to an “outperform” rating and decreased their price objective for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. Barrington Research boosted their price objective on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, BTIG Research increased their target price on shares of Haemonetics from $85.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $78.50.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $73.13 on Thursday. The firm has a market cap of $3.42 billion, a price-to-earnings ratio of 22.36, a P/E/G ratio of 0.91 and a beta of 0.43. The firm has a fifty day moving average price of $52.61 and a 200 day moving average price of $62.33. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $93.97. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The business had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the previous year, the company earned $1.12 EPS. The business’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, sell-side analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.